GlassScriptPhysician profile
Mir A Alikhan
NPI 1225127863
$1,880.48
in general payments reported to CMS, 2019-2025
27 companies · $32.27 in 2025
The $32.27 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $231 · 2021: $346 · 2022: $135 · 2023: $146 · 2024: $91.33 · 2025: $32.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.61 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $296.09 | 2019-2022 | |
| Incyte Corporation | $217.05 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $199.42 | 2019-2023 | Calquence |
| Genentech USA, INC. | $119.50 | 2019-2024 | Polivy, Lunsumio, Columvi |
| Novartis Pharmaceuticals Corporation | $109.79 | 2019-2024 | |
| Pfizer INC. | $100.19 | 2019-2021 | |
| Janssen Biotech, INC. | $86.06 | 2019-2021 | |
| Seagen INC. | $56.58 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $54.86 | 2019-2021 | |
| Genzyme Corporation | $54.24 | 2019-2021 | |
| Amgen INC. | $49.71 | 2019-2020 | |
| Eisai INC. | $44.89 | 2019-2020 | |
| Abbvie INC. | $32.27 | 2025 | |
| Astellas Pharma US INC | $27.26 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $25.05 | 2024 | Epkinly |
| Array Biopharma INC | $24.84 | 2019 | |
| Emd Serono, INC. | $22.52 | 2019 | |
| Puma Biotechnology, INC. | $20.93 | 2020 | |
| G1 Therapeutics, INC. | $19.79 | 2022 | |
| Kite Pharma, INC. | $18.35 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.49 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.26 | 2019 | |
| Mirati Therapeutics, INC. | $15.16 | 2023 | Krazati |
| Celgene Corporation | $14.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Alikhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.